ROS1基因突变非小细胞肺癌分子靶向治疗研究进展

doi:10.3760/cma.j.cn371439-20250810-00016

摘要/Abstract

摘要：

ROS1基因重排在非小细胞肺癌（NSCLC）中的发生率为1%~2%，其参与NSCLC细胞的增殖、转移和侵袭。ROS1-酪氨酸激酶抑制剂（TKI）的问世显著改善了ROS1基因突变NSCLC患者的预后，然而大部分患者在持续用药后出现了获得性耐药，严重挑战着肿瘤靶向药物的治疗效果。对于ROS1-TKI的分子耐药机制目前尚不完全清楚。进一步探讨ROS1融合基因的背景、突变方式、ROS1-TKI及其耐药机制，可以为ROS1-TKI耐药的NSCLC患者提供治疗新思路。

关键词: 癌，非小细胞肺, 分子靶向治疗, 抗药性，肿瘤, ROS1基因, 治疗学

Abstract:

The incidence of ROS1 gene rearrangement in non-small cell lung cancer （NSCLC） is 1%-2%. It is involved in the proliferation， metastasis and invasion of NSCLC cells. The advent of ROS1-tyrosine kinase inhibitors （TKIs） has significantly improved the prognosis of ROS1 gene mutant NSCLC patients. However， most patients have acquired resistance after continuous drug use， which seriously challenges the therapeutic effect of tumor targeted drugs. The molecular resistance mechanism of ROS1-TKIs is not completely understood. Further exploration of the background， mutation mode， ROS1-TKIs and resistance mechanism of ROS1 fusion gene can provide new treatment ideas for NSCLC patients resistant to ROS1-TKIs.

Key words: Carcinoma， non-small-cell lung, Molecular targeted therapy, Drug resistance， neoplasm, ROS proto-oncogene 1, Therapeutics

赵悦, 宋陈晨, 梁天赐, 王辉, 问婷芝, 戎彪学. ROS1基因突变非小细胞肺癌分子靶向治疗研究进展[J]. 国际肿瘤学杂志, 2026, 53(2): 105-110.

Zhao Yue, Song Chenchen, Liang Tianci, Wang Hui, Wen Tingzhi, Rong Biaoxue. Research progress of molecular targeted therapy of ROS1 gene mutation in non-small cell lung cancer[J]. Journal of International Oncology, 2026, 53(2): 105-110.

参考文献 49

[1]	Jeon H, Wang S, Song J, et al. Update 2025: management of non‑ small-cell lung cancer[J]. Lung, 2025, 203(1): 53. DOI: 10.1007/s00408-025-00801-x.
[2]	Shibuya M, Hanafusa H, Balduzzi PC. Cellular sequences related to three new onc genes of avian sarcoma virus (fps, yes, and ros) and their expression in normal and transformed cells[J]. J Virol, 1982, 42(1): 143-152. DOI: 10.1128/jvi.42.1.143-152.1982.
[3]	Matsushime H, Shibuya M. Tissue-specific expression of rat c-ros-1 gene and partial structural similarity of its predicted products with sev protein of Drosophila melanogaster[J]. J Virol, 1990, 64(5): 2117-2125. DOI: 10.1128/jvi.64.5.2117-2125.1990.
[4]	El-Deeb IM, Yoo KH, Lee SH. ROS receptor tyrosine kinase: a new potential target for anticancer drugs[J]. Med Res Rev, 2011, 31(5): 794-818. DOI: 10.1002/med.20206. pmid: 20687158
[5]	Li S, Zhang H, Chen T, et al. Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors[J]. Cancer Med, 2024, 13(8): e7201. DOI: 10.1002/cam4.7201.
[6]	Puchalski RB, Shah N, Miller J, et al. An anatomic transcriptional atlas of human glioblastoma[J]. Science, 2018, 360(6389): 660-663. DOI: 10.1126/science.aaf2666. pmid: 29748285
[7]	Shih CH, Chang YJ, Huang WC, et al. EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis[J]. Oncogene, 2017, 36(47): 6542-6554. DOI: 10.1038/onc.2017.262. pmid: 28759046
[8]	Bajrami I, Marlow R, van de Ven M, et al. E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer[J]. Cancer Discov, 2018, 8(4): 498-515. DOI: 10.1158/2159-8290.CD-17-0603. pmid: 29610289
[9]	Furcht CM, Muñoz Rojas AR, Nihalani D, et al. Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations[J]. Oncogene, 2013, 32(18): 2346-2355. DOI: 10.1038/onc.2012.240. pmid: 22777356
[10]	Charest A, Wilker EW, Mclaughlin ME, et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice[J]. Cancer Res, 2006, 66(15): 7473-81. DOI: 10.1158/0008-5472.CAN-06-1193. pmid: 16885344
[11]	Facchinetti F, Rossi G, Bria E, et al. Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition[J]. Cancer Treat Rev, 2017, 55: 83-95. DOI: 10.1016/j.ctrv.2017.02.010. pmid: 28342334
[12]	Lim SM, Yoo JE, Lim KH, et al. Rare incidence of ROS1 rearrangement in cholangiocarcinoma[J]. Cancer Res Treat, 2017, 49(1): 185-192. DOI: 10.4143/crt.2015.497.
[13]	He Y, Sheng W, Hu W, et al. Different types of ROS1 fusion partners yield comparable efficacy to crizotinib[J]. Oncol Res, 2019, 27(8): 901-910. DOI: 10.3727/096504019X15509372008132.
[14]	Kalla C, Gruber K, Rosenwald A, et al. ROS1 gene rearrangement and expression of splice isoforms in lung cancer, diagnosed by a novel quantitative RT-PCR assay[J]. J Mod Hum Pathol, 2016, 3(1): 25-34. DOI: 10.14312/2397-6845.2016-5.
[15]	Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269): pl1. DOI: 10.1126/scisignal.2004088.
[16]	Drilon A, Jenkins C, Iyer S, et al. ROS1-dependent cancers-biology, diagnostics and therapeutics[J]. Nat Rev Clin Oncol, 2021, 18(1): 35-55. DOI: 10.1038/s41571-020-0408-9.
[17]	Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001[J]. Ann Oncol, 2019, 30(7): 1121-1126. DOI: 10.1093/annonc/mdz131. pmid: 31987379
[18]	Michels S, Massutí B, Schildhaus HU, et al. Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase Ⅱ clinical trial[J]. J Thorac Oncol, 2019, 14(7): 1266-1276. DOI: 10.1016/j.jtho.2019.03.020.
[19]	Patil T, Smith DE, Bunn PA, et al. The incidence of brain metastases in stage Ⅳ ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib[J]. J Thorac Oncol, 2018, 13(11): 1717-1726. DOI: 10.1016/j.jtho.2018.07.001.
[20]	Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020, 21(2): 261-270. DOI: 10.1016/S1470-2045(19)30690-4. pmid: 31838015
[21]	Dziadziuszko R, Krebs MG, De Braud F, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer[J]. J Clin Oncol, 2021, 39(11): 1253-1263. DOI: 10.1200/JCO.20.03025.
[22]	Peters S, Gadgeel SM, Mok T, et al. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial[J]. Nat Med, 2024, 30(7): 1923-1932. DOI: 10.1038/s41591-024-03008-4. pmid: 38898120
[23]	Zhang H, Li X, Zhang Z, et al. Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients[J]. Medicine (Baltimore), 2023, 102(29): e33543. DOI: 10.1097/MD.0000000000033543.
[24]	Calles A, Alonso M, Martín-Martorell P, et al. Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain[J]. Cancer Treat Res Commun, 2025, 43: 100905. DOI: 10.1016/j.ctarc.2025.100905.
[25]	Yu ZQ, Wang M, Zhou W, et al. ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance[J]. J Drug Target, 2022, 30(8): 845-857. DOI: 10.1080/1061186X.2022.2085730.
[26]	Zhou Y, Jiang W, Zeng L, et al. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab[J]. Lung Cancer, 2020, 143: 55-59. DOI: 10.1016/j.lungcan.2020.03.019. pmid: 32208297
[27]	Lin JJ, Choudhury NJ, Yoda S, et al. Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer[J]. Clin Cancer Res, 2021, 27(10): 2899-2909. DOI: 10.1158/1078-0432.CCR-21-0032. pmid: 33685866
[28]	Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer[J]. JCO Precis Oncol, 2017, 2017: PO.17. 00063. DOI: 10.1200/PO.17.00063.
[29]	Ku BM, Bae YH, Lee KY, et al. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer[J]. Invest New Drugs, 2020, 38(2): 360-368. DOI: 10.1007/s10637-019-00795-3.
[30]	Davies KD, Mahale S, Astling DP, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer[J]. PLoS One, 2013, 8(12): e82236. DOI: 10.1371/journal.pone.0082236.
[31]	Dagogo-Jack I, Rooney M, Nagy RJ, et al. Molecular analysis of plasma from patients with ROS1-positive NSCLC[J]. J Thorac Oncol, 2019, 14(5): 816-824. DOI: 10.1016/j.jtho.2019.01.009. pmid: 30664990
[32]	Chen R, Jian Y, Liu Y, et al. ALK-rearranged and EGFR wild-type lung adenocarcinoma transformed to small cell lung cancer: a case report[J]. Front Oncol, 2024, 14: 1395654. DOI: 10.3389/fonc.2024.1395654.
[33]	Lin JJ, Langenbucher A, Gupta P, et al. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition[J]. NPJ Precis Oncol, 2020, 4(1): 21. DOI: 10.1038/s41698-020-0127-9.
[34]	Roupakia E, Chavdoula E, Karpathiou G, et al. Canonical NF-κB promotes lung epithelial cell tumour growth by downregulating the metastasis suppressor CD82 and enhancing epithelial-to-mesenchymal cell transition[J]. Cancers (Basel), 2021, 13(17): 4302. DOI: 10.3390/cancers13174302.
[35]	Hubbeling H, Choudhury N, Flynn J, et al. Outcomes with local therapy and tyrosine kinase inhibition in patients with ALK/ROS1/RET-rearranged lung cancers[J]. JCO Precis Oncol, 2022, 6: e2200024. DOI: 10.1200/PO.22.00024.
[36]	Tsai CJ, Yang JT, Shaverdian N, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study[J]. Lancet, 2024, 403(10422): 171-182. DOI: 10.1016/S0140-6736(23)01857-3. pmid: 38104577
[37]	Schneider JL, Muzikansky A, Lin JJ, et al. A phase 2 study of lorlatinib in patients with ROS1-rearranged lung cancer with brain-only progression on crizotinib[J]. JTO Clin Res Rep, 2022, 3(7): 100347. DOI: 10.1016/j.jtocrr.2022.100347.
[38]	Li W, Xiong A, Yang N, et al. Efficacy and safety of taletrectinib in Chinese patients with ROS1⁺non-small cell lung cancer: the phase Ⅱ trust-Ⅰ study[J]. J Clin Oncol, 2024, 42(22): 2660-2670. DOI: 10.1200/JCO.24.00731.
[39]	van der Wel JWT, Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: an update from the 2024 annual ESMO meeting[J]. Lung Cancer, 2025, 204: 108490. DOI: 10.1016/j.lungcan.2025.108490.
[40]	Boulanger MC, Schneider JL, Lin JJ. Advances and future directions in ros1 fusion-positive lung cancer[J]. Oncologist, 2024, 29(11): 943-956. DOI: 10.1093/oncolo/oyae205.
[41]	Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer[J]. N Engl J Med, 2024, 390(2): 118-131. DOI: 10.1056/NEJMoa2302299.
[42]	Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target[J]. Nat Cancer, 2023, 4(3): 330-343. DOI: 10.1038/s43018-023-00515-0.
[43]	Hartmaier RJ, Markovets AA, Ahn MJ, et al. Osimertinib plus savolitinib to overcome acquired met-mediated resistance in epidermal growth factor receptor-mutated, met-amplified non-small cell lung cancer: tatton[J]. Cancer Discov, 2023, 13(1): 98-113. DOI: 10.1158/2159-8290.CD-22-0586.
[44]	Dagogo-Jack I, Kiedrowski LA, Heist RS, et al. Efficacy and tolerability of ALK/MET combinations in patients with ALK-rearranged lung cancer with acquired met amplification: a retrospective analysis[J]. JTO Clin Res Rep, 2023, 4(8): 100534. DOI: 10.1016/j.jtocrr.2023.100534.
[45]	Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry[J]. Ann Oncol, 2019, 30(8): 1321-1328. DOI: 10.1093/annonc/mdz167. pmid: 31125062
[46]	Guisier F, Dubos-Arvis C, Viñas F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018[J]. J Thorac Oncol, 2020, 15(4): 628-636. DOI: 10.1016/j.jtho.2019.12.129.
[47]	Yan N, Huang S, Li L, et al. Case report: durable response to immuno-chemotherapy in a case of ros1 fusion-positive advanced lung adenocarcinoma: a case report[J]. Front Pharmacol, 2022, 13: 898623. DOI: 10.3389/fphar.2022.898623.
[48]	Bylicki O, Tomasini P, Radj G, et al. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage ⅢB/Ⅳ non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: a multicentre phase Ⅱ open-label non-randomised study GFPC 06-2018[J]. Eur J Cancer, 2023, 183: 38-48. DOI: 10.1016/j.ejca.2023.01.014.
[49]	Watanabe H, Ichihara E, Kayatani H, et al. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers[J]. Cancer Sci, 2021, 112(5): 1853-1864. DOI: 10.1111/cas.14801.